Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.42 |
| ▸ | CFTR | P13569 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9269293 | 0.87 | GRM6 (0.38) | MMP2GRM6ALDH1A1HSD17B10CFTR | |
| SCHEMBL2730411 | 0.86 | GRM6 (0.49) | MMP2GRM6ALDH1A1HSD17B10CFTR | |
| SCHEMBL27651123 | 0.86 | GRM6 (0.42) | MMP2GRM6ALDH1A1HSD17B10CFTR | |
| SCHEMBL6577861 | 0.85 | ALOX15 (0.43) | GRM6ALDH1A1HSD17B10ALOX15KDM4E | |
| SCHEMBL9269299 | 0.83 | SMN1; SMN2 (0.36) | MMP2GRM6ALDH1A1HSD17B10CFTR | |
| SCHEMBL6995362 | 0.83 | ALDH1A1 (0.53) | GRM6ALDH1A1HSD17B10CFTRCASP7 | |
| SCHEMBL31330407 | 0.81 | ALOX15 (0.43) | GRM6ALDH1A1HSD17B10ALOX15KDM4E | |
| SCHEMBL8892028 | 0.81 | ALDH1A1 (0.59) | MMP2GRM6ALDH1A1HSD17B10CFTR | |
| SCHEMBL7813319 | 0.81 | CCR2 (0.38) | GRM6ALDH1A1HSD17B10KDM4EHPGD | |
| SCHEMBL20928673 | 0.81 | MAPT (0.47) | GRM6ALDH1A1HSD17B10ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170265-A1 | DIAZONIUM COMPOUNDS AND METHODS OF USE FOR DNA CLEAVAGE | NEW YORK UNIVERSITY (US) | 2025-05-29 | — | — | US | disclosed |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-29 | — | — | US | disclosed |
| EP-4301368-A1 | BET PROTEIN INHIBITORS AND USE THEREOF | The Regents of the University of California (US) | 2024-01-10 | — | — | EP | disclosed |
| US-10849981-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | KemPham, Inc. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2020-11-17 | — | — | US | disclosed |
| US-10654863-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | KEMPHARM, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10577376-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | KEMPHARM, INC. (US) | 2020-03-03 | — | — | US | disclosed |
| US-20200038383-A1 | IMMEDIATE-RELEASE ABUSE DETERRENT COMPOSITIONS OR MEDICAMENTS FOR TREATING PAIN, ADD, ADHD AND OTHER SYNDROMES OR DISORDERS | ALTER DOMUS (US) LLC | 2020-02-06 | — | — | US | disclosed |
| EP-3560336-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | Kempharm, Inc. (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-2448407-B1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | KEMPHARM INC (US) | 2019-09-25 | — | — | EP | disclosed |
| CN-102480959-A | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | KEMPHARM INC | 2012-05-30 | — | — | CN | disclosed |
| EP-2448407-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | Kempharm, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110002990-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | ALTER DOMUS (US) LLC | 2011-01-06 | — | — | US | disclosed |
| EP-2086993-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | Zedira GmbH (DE) | 2009-08-12 | — | — | EP | disclosed |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2009-06-18 | — | — | US | disclosed |
| EP-1926730-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | AstraZeneca AB (SE) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008055488-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
| WO-2007030061-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-03-15 | — | — | WO | disclosed |
| US-4758552-A | Gonadoliberin derivatives containing an aromatic aminocarboxylic acid in the 6-position, pharmaceutical and veterinary compositions containing them and process for preparing same | INNOFINANCE ALTALANOS INNOVACIOS PENZINTEZET (HU) | 1988-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654863-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | CYP3A43, CYP2B6, CYP2D6 | MMP2 993/4885GRM6 939/4885ALDH1A1 262/4885 |
| US-20250170265-A1 | DIAZONIUM COMPOUNDS AND METHODS OF USE FOR DNA CLEAVAGE | OGG1, UNG, DNMT3A | MMP2 558/4885GRM6 3137/4885ALDH1A1 1349/4885 |
| US-20200038383-A1 | IMMEDIATE-RELEASE ABUSE DETERRENT COMPOSITIONS OR MEDICAMENTS FOR TREATING PAIN, ADD, ADHD AND OTHER SYNDROMES OR DISORDERS | OPRK1, OPRL1, OPRD1 | MMP2 1770/4885GRM6 163/4885ALDH1A1 45/4885 |
| US-20090156575-A1 | NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES | CCR8, CCR1, CCR10 | MMP2 4777/4885GRM6 649/4885ALDH1A1 1599/4885 |
| US-10836720-B2 | Inhibitors of integrin alpha 5 beta 1 and methods of use | ITGA5, ITGB5, ITGB1 | MMP2 640/4885GRM6 2076/4885ALDH1A1 339/4885 |
| US-20110229568-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | TGM2, TGM3, TGM1 | MMP2 1436/4885GRM6 1627/4885ALDH1A1 4170/4885 |
| US-10577376-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | CYP3A43, CYP2B6, CYP2D6 | MMP2 993/4885GRM6 939/4885ALDH1A1 262/4885 |
| US-20110002990-A1 | BENZOIC ACID, BENZOIC ACID DERIVATIVES AND HETEROARYL CARBOXYLIC ACID CONJUGATES OF HYDROCODONE, PRODRUGS, METHODS OF MAKING AND USE THEREOF | CYP2B6, CYP3A43, CYP2D6 | MMP2 722/4885GRM6 514/4885ALDH1A1 160/4885 |
| US-10849981-B2 | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof | CYP3A43, CYP2B6, CYP2D6 | MMP2 993/4885GRM6 939/4885ALDH1A1 262/4885 |
| US-20250171419-A1 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | NAMPT, NAPRT, NNMT | MMP2 2424/4885GRM6 3427/4885ALDH1A1 747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.